<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03986528</url>
  </required_header>
  <id_info>
    <org_study_id>2018YFC1707405</org_study_id>
    <nct_id>NCT03986528</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Kanglaite Injection (KLTi) in Advanced Non-Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>Clinical Trial on the Survival Advantage of Kanglaite Injection (KLTi) in Advanced Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jie Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Science and Technology of the People´s Republic of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Kanglaite Injection for&#xD;
      advanced non-small cell lung cancer(NSCLC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study include a multicenter, randomized, controlled post-market clinical trial.The&#xD;
      randomized clinical trial will enroll approximately 334 patients. Participants will be&#xD;
      randomly divided into experimental (n=167) and control groups (n=167).Patients in the&#xD;
      experimental group will receive Kanglaite Injection combination with first-line chemotherapy&#xD;
      based on NCCN Guidelines (2019.V3). Patients in the control group will receive first-line&#xD;
      chemotherapy based on NCCN Guidelines (2019.V3).The primary endpoint is PFS(progression free&#xD;
      survival).The research protocol was approved by the relevant ethics committees, and the study&#xD;
      was conducted according to the Declaration of Helsinki and Good Clinical Practice guidelines.&#xD;
      Patients gave written informed consent to participate in the trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 28, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival(PFS)</measure>
    <time_frame>Randomization until disease progression, death, or 12 months after randomized enrollment, whichever occurs first.</time_frame>
    <description>Progression Free Survival (PFS), as Determined by the Investigator using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Every two cycles (each cycle is 21-28 days) until disease progression, death, or 12 months after randomized enrollment, whichever occurs first.</time_frame>
    <description>ORR is defined as the percentage of participants who had a Complete Response (CR:Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed by RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One-Year Survival Rate</measure>
    <time_frame>Randomization until One year.</time_frame>
    <description>One-year survival rate refers to the proportion of patients with a survival period of more than one year starting from randomized enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life of the patient</measure>
    <time_frame>before and after each cycle of treatment, assessed up to 12 months after randomized enrollment</time_frame>
    <description>This will be measured with validated questionnaires (EORTC-QLQ C30) and Lung Cancer Symptom Scale(LCSS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Living ability of the patient</measure>
    <time_frame>before and after each cycle of treatment, assessed up to 12 months after randomized enrollment</time_frame>
    <description>This will be measured with validated questionnaires(ECOG) and Karnofsky performance status (KPS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood lipid</measure>
    <time_frame>every 41-56 days(2 cycles ) until disease progression, death, or assessed up to 12 months after randomized enrollment.</time_frame>
    <description>total cholesterol, triacylglycerides, high density cholesterol, low density cholesterol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>Baseline until disease progression,death, or assessed up to 12 months after randomized enrollment.</time_frame>
    <description>Percentage of Participants With Adverse Events in different arms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">334</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>Kanglaite Injection + Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Kanglaite Injection PLUS first-line chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>first-line chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kanglaite Injection+Chemotherapy</intervention_name>
    <description>Patients will receive investigator's choice of paclitaxel (135mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or pemetrexed (500mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or gemcitabine(1000mg/m2 by IV infusion on Days 1,8 of each 21-28 day cycle) PLUS cisplatin (75mg/m2 by IV infusion on Days 1 to 3 of each 21-28 day cycle) or carboplatin (AUC 6 by IV infusion on Days 1 of each 21-28 day cycle) according pathologic types. Patients with CR, PR, or SD after 4-6 cycles of platinum-based double chemotherapy regimens will receive non-platinum single-agent chemotherapy. The patients will also receive Kanglaite injection 200ml by IV infusion per day continuously for 14 days, commencing on the first day of chemotherapy.</description>
    <arm_group_label>Kanglaite Injection + Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Patients will receive investigator's choice of paclitaxel (135mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or pemetrexed (500mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or gemcitabine(1000mg/m2 by IV infusion on Days 1,8 of each 21-28 day cycle) PLUS cisplatin (75mg/m2 by IV infusion on Days 1 to 3 of each 21-28 day cycle) or carboplatin (AUC 6 by IV infusion on Days 1 of each 21-28 day cycle) according pathologic types. Patients with CR, PR, or SD after 4-6 cycles of platinum-based double chemotherapy regimens will receive non-platinum single-agent chemotherapy.</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A Histological or cytological confirmed diagnosis of Stage III-IV NSCLC, with no&#xD;
             history of anticancer treatment including chemotherapy;&#xD;
&#xD;
          -  Male or female aged 18-75years;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance score 0-2;&#xD;
&#xD;
          -  Life expectancy of at least 3 months;&#xD;
&#xD;
          -  At least one radiographically measurable lesion per RECIST 1.1;&#xD;
&#xD;
          -  Willing to join the clinic trail and sign informed consent;&#xD;
&#xD;
          -  Able to comply with scheduled visits and treatments.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of cerebral metastases;&#xD;
&#xD;
          -  Confirmed positive for expression of expression of epidermal growth factor receptor&#xD;
             (EGFR), activin receptor-like kinase (ALK), c-ros oncogene 1 (ROS1) mutation, or&#xD;
             programmed death-ligand 1 (PD-L1)(tumor proportion score [TPS≥ 50%] in a genetic test;&#xD;
&#xD;
          -  Participants with malignant pleural effusion underwent intrapleural injection&#xD;
             chemotherapy;&#xD;
&#xD;
          -  Current undergoing or preparing for treatment with target therapy;&#xD;
&#xD;
          -  Current undergoing or preparing for radiotherapy to the thorax;&#xD;
&#xD;
          -  Current undergoing or preparing treatment with tumor immunotherapy;&#xD;
&#xD;
          -  Currently undergoing lipid-decreasing treament;&#xD;
&#xD;
          -  Pregnant or breastfeeding woman;&#xD;
&#xD;
          -  Fertile patients who are unwilling or unable to take effective contraceptive measures&#xD;
             during the research period until 6 months after the study end later;&#xD;
&#xD;
          -  A history of mental disorders；&#xD;
&#xD;
          -  Severe and uncontrolled organic lesion or infection, including but not limited to&#xD;
             cardiopulmonary failure and renal failure，which lead to poor tolerance of&#xD;
             chemotherapy;&#xD;
&#xD;
          -  Participated in other clinical trials of small molecule research drugs within 28 days&#xD;
             prior to enrollment, or participated in other clinical trials of large molecule&#xD;
             research drugs within 3 months before enrollment;&#xD;
&#xD;
          -  Known allergy or intolerance to study medications;&#xD;
&#xD;
          -  Considered to be otherwise unsuitable for the clinical study by researchers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gao rui ke</last_name>
    <phone>+86 1088001192</phone>
    <email>gaork2015@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anhui Chest Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mei Chai, MM</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chongqing Cancer Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fangfei Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gansu Provincial Tumor Hospital</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xudong Lei</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangzhou University of Chinese Medicine</name>
      <address>
        <city>Guanzhou</city>
        <state>Guangdong</state>
        <zip>510405</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanrui Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xu Sun</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunan Academy of Traditional Chinese Medicine Affiliated Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Lou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunan Provincial Tumor Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Wu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital of Chinese Medicine</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>XuZhou Central Hospital</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Gao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Shandong University of Traditional Chinese Medicine</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiehui Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Longhua Hospital Shanghai University of Traditional Chinese Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lihua Zhu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yueyang Hospital of Integrated Traditional Chinese and Western Medicine,Shanghai University of Traditional Chinese Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200437</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ling Xu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanxi Provincial Cancer Hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Fourth Military Medical University Tangdu Hospital</name>
      <address>
        <city>Xian</city>
        <state>Shanxi</state>
        <zip>710038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Canjun Zhao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute &amp; Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhansheng Jiang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhejiang Chinese Medicine University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Pan</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 30, 2019</study_first_submitted>
  <study_first_submitted_qc>June 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2019</study_first_posted>
  <last_update_submitted>February 21, 2021</last_update_submitted>
  <last_update_submitted_qc>February 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</investigator_affiliation>
    <investigator_full_name>Jie Li</investigator_full_name>
    <investigator_title>Chief of Medical Department</investigator_title>
  </responsible_party>
  <keyword>Advanced Non-Small Cell Lung Cancer</keyword>
  <keyword>Kanglaite Injection</keyword>
  <keyword>Chinese Herbal Medicine</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>Progression-free Survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The results of the study will be issued to publications through scientific journals and conference reports. The anonymized datasets used and/or analyzed during the current study are available from the sponsor-investigator on reasonable request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

